Last reviewed · How we verify
NCT06810219
Augmented Reality BCI Longitudinal Study for Persons With Late Stage ALS
NA trial testing Cognixion ONE in ALS (Amyotrophic Lateral Sclerosis) in 10 participants. Currently enrolling.
30 August 2025
Quick facts
| Lead sponsor | Cognixion |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | device feasibility |
| Enrollment | 10 |
| Start date | 20 January 2025 |
| Primary completion | 30 August 2025 |
| Estimated completion | 31 October 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Cognixion ONE
Conditions studied
- ALS (Amyotrophic Lateral Sclerosis) — all drugs for ALS (Amyotrophic Lateral Sclerosis) →
Sponsor
Cognixion
Who can join
18 and older, any sex, with ALS (Amyotrophic Lateral Sclerosis). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is refine the usability of a BCI based communication platform. The study will take place in the greater Los Angeles area and will enroll up to 10 participants with late stage ALS. Each subject will receive a Cognixion Axon-R augmented reality brain computer interface and associated communication software. The study duration is 3 months for each participant. The key questions that will be addressed in this study are: 1. How quickly can participants learn and gain confidence with a pure BCI interface. 2. How effective are alternate input modalities including eye tracking for this use case. 3. Identify the extent to which generative AI based personalization impacts the communication quality. Key measures include: ITR - information transfer rate SUS - system usability scale
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06810219
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for ALS (Amyotrophic Lateral Sclerosis)
Currently open trials in the same condition.
- NCT07067229 — Non-invasive Brain Stimulation and Exercise Intervention for Patients With Motor Neuron Disease · NA · recruiting
- NCT07006571 — At-home Treatment With Cortico-spinal tDCS for Amyotrophic Lateral Sclerosis · NA · recruiting
- NCT07175935 — Amyotrophic Lateral Sclerosis Registry in Thailand · recruiting
- NCT07235111 — Omics Sciences for the Identification of Pathogenetic Mechanisms and Biomarkers in Neurodegenerative Diseases · recruiting
- NCT06363357 — The Effect of a Muscle-mimicking, Fabric-type Shoulder Orthosis on Functional Movements of the Upper Limb in Patients Wi · NA · recruiting
Other Cognixion trials
Trials by the same sponsor.
- NCT07209943 — Augmented Reality BCI Longitudinal Study for Persons With ALS, Stroke, TBI and SCI Utilizing Cognixion + Apple Vision Pr · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06810219 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cognixion
- Last refreshed: 5 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06810219.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing